Active — Not RecruitingPhase 4

Prospective Study of End Stage Renal Disease Patients With Coronary Artery Disease Treated by Oral Nicorandil

Japan268 participantsStarted 2008-06

Plain-language summary

Nicorandil is potentially effective to prevent cardiovascular events in patients with coronary artery disease (CAD) receiving hemodialysis. The purpose of this study is to prospectively investigate whether nicorandil is effective in reducing the incidence of cardiovascular events in patients with CAD on hemodialysis.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Eligible patients are who meet the following criteria: * Patient with previously diagnosed coronary artery disease (significant coronary artery stenosis is defined as \> 75% narrowing of the artery lumen) * Patients who continued hemodialysis for more than one month Exclusion Criteria: * Within one month after acute myocardial infarction * Within 3 months after coronary artery bypass graft (CABG) * Treatment with phosphodiesterase type 5 inhibitor * Candidates for carotid artery stenting * Severe disease requiring active medical treatment

What they're measuring

The primary endpoint is composite of :1) cardiovascular death 2)sudden cardiac death 3)nonfatal myocardial infarction 4)Hospitalization for recurrent symptomatic myocardial ischemia 5)stroke

Timeframe: 2 years

Trial details

NCT IDNCT01475123

SponsorKumamoto University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2011-06

View on ClinicalTrials.gov More Coronary Artery Disease trials